Zydelig: targeted B-cell malignancy treatment

Zydelig (idelalisib) can be used as monotherapy for follicular lymphoma refractory to two prior lines of treatment, and in combination with rituximab for chronic lymphocytic leukaemia after one prior therapy or first-line in patients with the 17p deletion or TP53 mutation who are unsuitable for chemo-immunotherapy.

by
The usual dose of Zydelig (idelalisib) is 150mg twice daily continued until disease progression or unacceptable toxicity occurs.
The usual dose of Zydelig (idelalisib) is 150mg twice daily continued until disease progression or unacceptable toxicity occurs.

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package